

## Media Release

### September 1, 2025

## Idorsia furthers the science of sleep and insomnia at World Sleep 2025

### Allschwil, Switzerland – September 1, 2025

Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World Sleep 2025, a global scientific congress bringing the best of sleep medicine and research, in Singapore from September 5-10, 2025.

Idorsia's scientific poster presentations at World Sleep 2025:

#### Real-world data assessment of abuse potential of insomnia therapies

A study to examine the real-world abuse potential of approved and off-label medications used for the treatment of insomnia, using data from the FDA Adverse Event Reporting System (FAERS) database.

- Real-world data on the abuse potential of medications for the treatment of insomnia. P. Saskin, W.V. McCall, D. Neubauer, A. Crucitti, P.P. Luyet, R. Jaziri, C. Vaillant. [Abstract available online](#)

#### Efficacy of daridorexant throughout the night

- Effect of daridorexant on wakefulness throughout the night: Post-hoc analysis of a randomised, double-blind, active reference (zolpidem) study in patients with insomnia disorder. B. Steiniger-Brach, O. Briasoulis, A. Olivieri, S. Pain, L. Palagini, D. Kunz, P.-A. Geoffroy. [Abstract available online](#)
- Effect of daridorexant on wakefulness throughout the night and morning sleepiness in patients with insomnia disorder. Y. Dauvilliers, G. Zammit, P.-P. Luyet, G. Braunstein, O. Briasoulis, A. Olivieri. [Abstract available online](#)

#### Impact of daridorexant in patients with insomnia and additional health conditions

- Efficacy and safety of daridorexant in women with insomnia disorder during menopausal transition: a subgroup analysis. O. Briasoulis, Z. Schaedel, C. Bassetti, S.M. Bertisch, P. Cassel, S. Palacios, C. Palmay, R. Silvestri, P. Stute, F. Trémollières, T. Bakker, S. Pain. [Abstract available online](#)
- Efficacy and safety of daridorexant in patients with chronic insomnia disorder and comorbid nocturia. K. Lederer, S. Schoffner, J.-E. Batista Miranda, R. Rowles, A. Olivieri, M. Meinel. [Abstract available online](#)

#### Characterization of patients with insomnia disorder

The largest clinical characterization of patients with insomnia disorder to date. Drawing on data from more than 5000 patients screened in the Phase 3 daridorexant program, these analyses provide important insights into the significant and wide-ranging impact of insomnia disorder on objective and subjective nighttime symptoms and daytime functioning. Subgroup analyses by sex and age provide important insights on how insomnia disorder may affect different patient populations.

- The impact of insomnia disorder on the night and the day: analysis of polysomnography and subjective parameters from a large clinical trial database. M. Fernandes, A. Olivieri, O. Briasoulis, J. Laurent, C. Liguori. [Abstract available online](#)
- The impact of insomnia disorder on the night and the day in older and younger adults. M. Fernandes, A. Olivieri, O. Briasoulis, J. Laurent, C. Liguori. [Abstract available online](#)

- The impact of insomnia disorder on the night and the day in males and females. M. Fernandes, A. Olivieri, O. Briasoulis, J. Laurent, C. Liguori. [Abstract available online](#)

### **Educational symposium**

On Tuesday, September 9, from 12:45 to 14:15, Idorsia will host an educational symposium featuring experts David Neubauer (US), Lu Lin (China), Atul Khullar (Canada), Laura Palagini (Italy), and Claudio Liguori (Italy). The symposium will explore the link between insomnia and neurological or psychiatric comorbidities, focusing on the role of orexin. New clinical and real-world data on daridorexant will be presented, alongside practical strategies for managing insomnia in patients with comorbidities through case discussions. The event will conclude with a Q&A and panel discussion to foster expert-attendee dialogue.

### **About World Sleep 2025**

World Sleep 2025 will be the 18<sup>th</sup> World Sleep Congress. This congress facilitates an international discussion forum and collaboration among sleep societies and sleep professionals. Sleep clinicians, technologists, trainees, educators, and scientists from around the world will meet to advance knowledge on sleep science, sleep in public health, sleep health, and sleep-wake disorders, their diagnosis and treatments. World Sleep Society seeks to maximize learning both from formal presentations by the leading experts in their fields and from informal discussion groups emphasizing opportunities for networking and member participation.

---

### **Notes to the editor**

#### **About Idorsia**

The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

#### **For further information, please contact:**

Investor & Media Relations

Idorsia Pharmaceuticals Ltd, Hegenheimmattweg 91, CH-4123 Allschwil

+41 58 844 10 10

investor.relations@idorsia.com – media.relations@idorsia.com – [www.idorsia.com](http://www.idorsia.com)

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "intend", "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.